Brian Ellis

Sodium-glucose cotransporter 2 inhibitors produce an off-target effect on blood pressure in type 2 diabetes patients.

Frequent hot flashes in younger women were linked to endothelial function, providing more insight into the cardiovascular disease risk status of patients.

A large, initial reduction in hemoglobin A1c (HbA1c) and achievement of low HbA1c levels 6 months after metformin initiation lowered the risk for cardiovascular events and death in patients with type 2 diabetes.

Medical malpractice expert Michelle Mello, JD, PhD, talks malpractice reform in a changing political landscape.

A systematic review of BMI and major adverse events in AF concluded that further evidence is necessary to clarify the relationship between obesity and AF.

Despite being a relatively new concept in the US, informed consent of study participants in medical research is ethically essential.

Researchers analyzed the effects of lowered blood pressure in patients with and without diabetes.

Katherine A. Roberts, MD, FACE, ECNU, discusses her experience with opting out of Medicare and offers advice to physicians considering doing the same.

LEADER trial results demonstrated that liraglutide lowered first occurrence of death from cardiovascular causes in patients with type 2 diabetes.

Ixmyelocel-T therapy reduced clinical cardiac events and improved patient outcomes.